Wound Management News

An analysis of 112 Veterans Affairs Medical Centers found that admission prevalence of methicillin-resistant Staphylococcus aureus was predictive of the disease’s acquisition rate, and vice versa.

CHICAGO -- Elizabeth Tanzi, MD, a dermatologist at the Washington Institute of Dermatologic Laser Surgery, Washington, DC, reported on laser skin resurfacing at the American Society for Dermatologic Surgery annual meeting.

CHICAGO − The set-back suturing technique resulted in superior wound eversion and better cosmetic outcomes compared with the current standard of care, the buried vertical mattress suture, according to research presented at the American Society for Dermatologic Surgery annual meeting.

CHICAGO — Forward-thinking technology, from laser treatment for port-wine stains and acne to harvesting full thickness columns of skin to place in recent wounds and creating epidermal blisters to heal vitiligo, was presented during a lecture at the American Society for Dermatologic Surgery annual meeting.

There were an estimated 30,800 fewer invasive methicillin-resistant Staphylococcus aureus infections reported in the United States in 2011 compared with 2005, according to recent data published in JAMA Internal Medicine.

The Department of Health and Human Services has awarded a $7.8 million contract to Novan Therapeutics to develop a nitric oxide-based therapy for topically treating thermal burns, the drug development company has announced.

Medical students who used computer-assisted learning performed better than those who used standard, printed materials to study before performing a rhomboid flap on a skin model, according to recent study results.

Two minimally invasive techniques to treat patients with varicose veins have become alternatives to traditional surgery, according to information presented at the American Academy of Dermatology’s Annual Summer Meeting in New York.

Pressure ulcers in children, primarily caused by medical devices, were reduced by 50% in a pediatric ICU after development of a quality-improvement program, according to study results.

RXi Pharmaceuticals recently announced positive phase 1 study results regarding its RXI-109 for treatment of abnormal dermal scars, including hypertrophic scars and keloids in conjunction with scar revision surgery.